Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy

Haematologica

Volumn 96, Issue 3, 2011, Pages 15-

  Eskazan, Ahmet Emre ^a   Soysal, Teoman ^a   Ongoren, Seniz ^a   Gulturk, Emine ^a   Ferhanoglu, Burhan ^a   Aydin, Yildiz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chronic myeloid leukemia; Dasatinib; Pleural and pericardial effusion

Indexed keywords

DASATINIB; FUROSEMIDE; GLUCOCORTICOID; IMATINIB;

ADULT; AGED; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; LOW DRUG DOSE; MALE; PERICARDIAL EFFUSION; PLEURA EFFUSION; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; DIURETICS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUROSEMIDE; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIAZOLES; TURKEY;

EID: 79952358361     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.040048     Document Type: Letter

References (4)

1. Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer G, Schloegl E, Valent P. Extensive pleural and pericardial effusion in CML during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2010 Oct 7. [Epub ahead of print]
2. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med. 2006;354(24):2531-41.
3. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28(3):398-404.
4. Masiello D, Gorospe G 3rd, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol. 2009;2:46.